In the past 15 years, there has been a 22% increase in the national suicide rate in the United States, 1 while the total number of psychiatric hospital beds in the United States decreased from 34 to 22 beds per 100 000 residents. 2 Bastiampillai et al 2 suggest that the availability of psychiatric hospital beds may be a risk factor in a complex network of suicide risk factors.
Methods | We obtained state-level data from the Area Health Resource File on the number of psychiatric hospital beds (private and public short-term general hospitals), the number of substance abuse beds, 3 suicide rates, 1 and per capita mental health spending from 1999 to 2013. 4 Between-state and withinstate associations between psychiatric hospital beds, substance abuse hospital beds, mental health spending, and suicide rates were statistically estimated using a hybrid mixedeffects Poisson regression model (with annual state population size used as an offset). 5 In the hybrid model, the betweenstate effect is estimated from the mean of the predictor over time and the within-state effect from the mean-deviation for each year. As confirmed with the University of Chicago institutional review board, the analysis of state-level aggregated US Centers of Disease Control and Prevention data is exempt from approval because all records are deidentified, and no informed consent is required.
Results | The simple inverse association is clearly apparent when considering the parallel time series only (Figure, A) . However, the overall association is produced by between-state differences in the availability of psychiatric hospital beds (risk ratio, 0.987; 95% CI, 0.981-0.993; P < .001), accounting for a 1.32% increase in the annual suicide rate per 1 fewer psychiatric hospital bed per 100 000 residents (Figure, B) . However, there is no within-state association between changes in the number of psychiatric beds and changes in suicide rates (risk ratio, 1.00; 95% CI, 0.998-1.004; P = .50), despite considerable within-state variability in psychiatric hospital bed availability (Figure, C ). In addition, there were no significant between-or within-state effects of the availability of substance abuse beds on suicide rates. Finally, we found a small but significant between-state inverse effect of mental health spending on suicide rates (risk ratio, 0.999; 95% CI, 0.998-.999; P = .04), indicating a 0.01% decrease in the suicide rate for every dollar spent on mental health spending. However, there was no significant within-state association.
Discussion | The availability of psychiatric hospital beds and substance abuse beds in short-term general hospitals was not causally related to suicide rates. Some between-state associations were found; however, they were confounded with other statelevel differences. Yoon and Bruckner 6 found an overall inverse association between the state-level availability of public psychiatric hospital beds and suicide rates; however, our analysis suggests that this was a between-state association, and that changing the availability of psychiatric hospital beds within a given state will not reduce suicide rates. Changes in the number of substance abuse beds and amount of mental health expenditures were similarly unrelated to within-state changes in suicide rates. Our study is limited by the lack of available data on longterm psychiatric hospitals and stratification by public and private hospitals.
Our findings indicate that attention should focus on determining how existing psychiatric beds are used rather than their absolute number. What are the proportions of high-risk patients being treated as outpatients vs inpatients, and how do their suicide rates compare after adjusting for risk profiles? Suicide risk is linked to rates of the diagnosis of major depression and how effectively it is treated at the outpatient level. Given that the US Centers for Disease Control and Prevention data on suicidal behavior, psychiatric diagnoses, and treatment in 18 states indicate that from 2005 to 2010, the rate of people receiving psychiatric treatment before dying of suicide was only 28.5%, there is considerable room for improvement. By focusing on hospital bed capacity, we may miss more fundamental deficits in detecting and treating patients at risk for suicide.
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COMMENT & RESPONSE Network Meta-analysis in Mental Health Research
To the Editor We applaud the attempt by Brunoni et al 1 to shed light on the comparative efficacy and safety of various repetitive transcranial magnetic stimulation (rTMS) strategies for treating depressive disorders by performing a network metaanalysis (NMA) on the extant published literature. The unique ability of NMA to leverage indirect evidence for a treatment's efficacy from a network of clinical trials is a potential advantage; however, as pointed out by Mills et al, 2 it can also produce distorted results when the analysis is applied incautiously to treatments (nodes) that are not well connected in the network, ie, those only studied against 1 or 2 comparators. It is no surprise that the 3 TMS strategies that were found not to be more efficacious than sham TMS in Brunoni and colleagues' NMA were the 3 that have only been studied against sham and thus could not benefit from indirect efficacy evidence from studies against other treatments. The potentially distorting effects of indirect evidence unevenly advantaging certain treatments is illustrated by comparing the remissionbased findings for primed TMS (pTMS) and deep TMS (dTMS). The evidence for the efficacy of dTMS derives from a single multicenter randomized clinical trial (eFigure 2A in Supplement 2) 1 in which dTMS produced significantly greater remission rates than sham TMS (direct efficacy evidence). With no study comparing it with another rTMS strategy, dTMS did not strongly benefit from indirect efficacy evidence and it was found not to be more efficacious than sham. The evidence for the remission efficacy of pTMS also derives from a single study, a head-to-head comparison with bilateral TMS in which both treatments produced comparable remission rates. However, unlike dTMS, the efficacy of pTMS was bolstered in the NMA owing to evidence suggesting that bilateral TMS is superior to sham (indirect efficacy evidence). As a result, the authors concluded that pTMS was more efficacious than sham and, in fact, the most efficacious rTMS intervention along with bilateral TMS, despite the fact that the lack of a sham treatment arm in the 1 pTMS study precludes the ability to rule out the possibility both pTMS and bilateral TMS were no more efficacious than placebo. When considering the evidence for superiority relative to sham, most investigators and clinicians would consider the direct superiority test of dTMS stronger than the indirect noninferiority of pTMS to bilateral TMS. However, the analysis by Brunoni et al 1 resulted in the opposite conclusions, calling into question the practical utility of their analysis.
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